Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?
MetadataShow full item record
Giele, Carolien and Moore, Hannah and Bayley, Kathy and Harrison, Catherine and Murphy, Denise and Rooney, Kylie and Keil, Anthony D. and Lehmann, Deborah (2007) Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?, Vaccine 25:2379-2384.
Copyright 2007 Elsevier. All rights reserved
Enhanced surveillance for invasive pneumococcal disease (IPD) has been ongoing in Western Australia since 1996. We describe the epidemiology of invasive pneumococcal disease in children aged <2 years between 1996 and 2005. Pneumococcal conjugate vaccine has been offered to Aboriginal children and other high-risk children since July 2001 and to all Australian children since January 2005. A total of 1655 IPD cases were reported of whom 361 (55 Aboriginal) were aged <2 years. From 1996 2001 to 2002 2005, IPD incidence declined from 192 to 124/100,000/annum in Aboriginal children and from 70 to 56/100,000/annum in non-Aboriginal children. Incidence of IPD due to vaccine serotypes (VT) declined from 118 to 43/100,000/annum (p = 0.05) in Aboriginal children and from 59 to 45/100,000/annum in non-Aboriginal children (p < 0.001), with no increased incidence of disease due to non-vaccine serotypes. Continued surveillance is essential to measure the impact of the childhood pneumococcal conjugate vaccination program on IPD incidence and to identify the emergence of disease due to non-vaccine serotypes.
Showing items related by title, author, creator and subject.
Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in AustraliaGidding, H.; McCallum, L.; Fathima, P.; Moore, H.; Snelling, Thomas; Blyth, C.; Jayasinghe, S.; Giele, C.; de Klerk, N.; Andrews, R.; McIntyre, P. (2018)Background: Most studies use indirect cohort or case-control methods to estimate vaccine effectiveness (VE) of 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease (IPD). ...
No evidence for impaired humoral immunity to pneumococcal proteins in Australian Aboriginal children with otitis mediaThornton, R.; Kirkham, L.; Corscadden, K.; Coates, H.; Vijayasekaran, S.; Hillwood, J.; Toster, S.; Edminston, P.; Zhang, Guicheng; Keil, A.; Richmond, P. (2017)Background: The Australian Aboriginal population experiences disproportionately high rates of otitis media (OM). Streptococcus pneumoniae is one of the main pathogens responsible for OM and currently no vaccine offering ...
Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccinationVan Den Biggelaar, A.; Richmond, P.; Fuery, A.; Anderson, D.; Opa, C.; Saleu, G.; Lai, M.; Francis, J.; Alpers, Michael Philip; Pomat, W.; Lehmann, D. (2017)Trial design: In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose ...